In the field of vaccine，great changes will occur in one year，Especially when it involves large trading operations。In an analysis report made in EvaluatePharma's latest analysis of vaccine sales，GlaxoSmot (GSK) will jump on the list with a sales of more than $ 8 billion by 2022，and last year only ranked fourth。

 

  Previous，EvaluatePharma predicted，Merck (Merck) will lead the vaccine industry in 2020，Following the following is PFIZER、GSK and Sanofi。

 

  So, how to explain the changes in prediction?

 

  Asset exchange assist GSK to the top

 

  Evaluate Pharma predicting the transaction director Antonio & Middot; Antonio Iervolino pointed out，GSK's status is significantly enhanced，The main reason is，Last year it completed stake betting appthe asset exchange transaction with Novartis，I got the other party’s vaccine business。

 

  As of now，GSK operates Nohua's vaccine combination products well。EvaluatePharma estimate，From now to 2022，GSK's vaccine business will increase at a rate of 6%，and finally sit in this field with sales of $ 8.55 billion in sales。

 

  This data is much higher than the $ 5.56 billion sales of GSK vaccine products in 2015，The latter data must be behind other large vaccine manufacturers。

 

  GSK's promising vaccine product is Shingrix，EvaluatePharma means，By 2022，This product is expected to achieve $ 1 billion in sales，to help the company's status in the field of vaccine。This shingles vaccine is currently in the process of submitting approval materials to the US FDA，Clinical trials indicate，It can protect the elderly with a 90%age of 70 or more。

 

  It is expected to be 2022，Sanofi will take the second overlap in the vaccine industry，More prediction analysis made by EvaluatePharma last year。The company's vaccine business is expected to grow at a rate of 5%per year，By 2022, sales reached 8.29 billion US dollars。This kind of expansion power is expected to be from Pentacel、FLUZONE and its newly developed dengue hot vaccine DENGVAXIA。

 

  but，At present，Sanofi encountered trouble on the promotion of Dengvaxia，The second quarter of this year，The sales of the vaccine are only 1 million euros。Sanofi executives said，This vaccine may reach less than 200 million euros of sales expectations this year。

 

  My stake betting appAccording to the previous predictions of EvaluatePharma，Merhado and Pfizer in 2020 will lead the vaccine industry，Its sales will be listed in one、Two digits。But now，Elwalno said，These two companies will face similar problems in the next five years: Gardasil and Prevnar, which have been listed on sale, are expected to slow down，and the new vaccine R & D line does not seem to make the investment community feel excited。

 

 

  Pfizer can borrow mergers and acquisitions to catch up

 

  Facts，Pfizer's vaccine business has developed greatly，This is mainly due to its super product PREVNAR 13)。but，This growth rate may be difficult to follow。Last year，Peer's sales reached $ 6.3 billion，但EvaluatePharma prediction，This number will drop to $ 6 billion by 2022。EvaluatePharma estimate，The annual sales of the vaccine in the next 5 years will decrease at a rate of 1%per year。

 

  and as early as 2014，Pfizer has gained a huge driving force，At that time，American Disease Control and Prevention Center (CDC) recommends that Peer is used for adults over 65 years old。but，According to the data cited by Pfizer at the recent call meeting，Adults over 65 years old in the United States have accepted immune vaccination。

 

  According to the performance report of the second quarter of this year，Peer's revenue decline in the US market offsets the growth of other drugs in Pfizer。Because Peer's initial use rate is higher，Compared with the second quarter of last year，Pfizer's future rushing opportunity has been smaller。

 

  stake sports betting appbut，As the FDA recently expanded Peer's approval for adults aged 18 to 49，The vaccine may usher in boosting opportunities。This expansion approval makes Peer's label closer to a suggestion made by CDC in 2012，CDC recommended to make immune function defects、Adults who are aged 19 and over vaccine the vaccine。

 

  EvaluatePharma prediction，From now to 2022，Vaccine products of Pfizer and Meridon will increase at a rate of 2%per year，Below the average growth rate of 5%lower than the industry。It is expected to be 2022，Pfizer's vaccine business will achieve sales of $ 7.4 billion，Merhadon's data is $ 7.2 billion。

 

  but，Elwrino pointed out，Pfizer has always been active in the field of vaccine mergers and acquisitions，So，Pfizer's sales data may be higher，This is not fully reflected in the long -term forecast that is currently made。

 

  Looking at it overall，By 2022，GSK、Sanofi、Pfizer and Merhadon are expected to account for 80%of the vaccine market，This also proves，Competition in this industry requires a certain scale and strength。including Novartis、CSL、Emerurs Biosolutions、Mitsubishi Tianbian、Some small vaccine manufacturers, including Anstela and Astailai and Dynavax, are expected to be in a downstream position。

 

  EvaluatePharma prediction，By 2022，Among the best -selling vaccine products in the world，HPV vaccine Gardasil in Merosha Dong will be ranked second，Sales reached US $ 2.47 billion，Far behind Peer's primary position。Sanofi's influenza vaccine Fluzone stake online sports bettingand for white throat、tetanus、Bail cough、Pntor Pentacel, a vaccine of influenza Bacteria (DTAP/HIB/POLIO), will be ranked third and fourth in the third and fourth bits，GSK's white throat、tetanus、Bail cough、Hepatitis B and Pediaarix (DTP/HEP B/Polio) vaccine is expected to be ranked fifth。